Mereo BioPharma Group (NASDAQ:MREO) Upgraded at Zacks Investment Research

Mereo BioPharma Group (NASDAQ:MREO – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports.

According to Zacks, “Mereo BioPharma Group PLC is a biopharmaceutical company. It is focused on development and commercialization of therapeutics for patients with rare diseases. The company’s product pipeline includes BPS-804, MPH-966, BCT-197, BGS-649, Navicixizumab and Etigilimab which are in clinical stage. Mereo BioPharma Group PLC is based in London, United Kingdom. “

Separately, SVB Leerink restated a “buy” rating and issued a $8.00 price target on shares of Mereo BioPharma Group in a research note on Friday, April 1st.

NASDAQ MREO opened at $0.92 on Friday. The company has a current ratio of 7.92, a quick ratio of 7.92 and a debt-to-equity ratio of 0.16. Mereo BioPharma Group has a fifty-two week low of $0.85 and a fifty-two week high of $3.75. The stock has a 50-day simple moving average of $1.22 and a two-hundred day simple moving average of $1.62.

A number of large investors have recently bought and sold shares of MREO. ProShare Advisors LLC purchased a new stake in Mereo BioPharma Group during the 4th quarter worth approximately $25,000. Clear Harbor Asset Management LLC purchased a new stake in Mereo BioPharma Group during the 4th quarter worth approximately $27,000. Oppenheimer & Co. Inc. purchased a new stake in Mereo BioPharma Group during the 3rd quarter worth approximately $46,000. Bluefin Capital Management LLC purchased a new stake in Mereo BioPharma Group during the 4th quarter worth approximately $60,000. Finally, Shay Capital LLC purchased a new stake in Mereo BioPharma Group during the 4th quarter worth approximately $77,000.

About Mereo BioPharma Group (Get Rating)

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor.

Further Reading